IsoTis Secures Broad Distribution Deal for OsSatura™ Dental
Agreement signed with BEGO Semados for dental applications

Lausanne / Bilthoven, March 27, 2003 – At the world trade fair for dental technology and dentistry, IDS, in Köln, Germany, biosurgery company IsoTis S.A. (SWX/Euronext Amsterdam: ISON) signed a distribution agreement for its osteoinductive bone substitute OsSatura™ with leading dental technology company BEGO. The agreement covers exclusive distribution rights of OsSatura™ Dental in Europe, and, potentially, in the US, and Rest of the World. The exact terms of the agreement were not disclosed.

OsSatura™ is the first synthetic bone substitute to be granted the CE mark on the basis of its osteoinductivity claim, and it was launched by IsoTis in early February. The company expects OsSatura to become a major product in the rapidly developing dental market that is increasingly relying on innovative technologies and products. With its unique combination of osteoconductivity and osteoinductivity properties, OsSatura is well-positioned to challenge the standard demineralized bone matrix (DBM) products. DBM products, which are mostly produced from bovine bone, have been under increased pressure due to concerns related to disease transfer.

Jacques R. Essinger Ph.D., Chief Executive Officer of IsoTis, said, "We are very happy to secure the distribution of OsSatura in the dental field, shortly after receiving European market approval. We are also very pleased to have BEGO as our commercial partner in this growing market for bone graft substitutes. BEGO has a global presence, an excellent reputation for reliable and innovative dental applications, and the proven ability to market these. With this agreement we are taking a big step towards meeting our sales targets."

Christoph Weiss, Managing Director of BEGO said, "As the first commercially available synthetic bone filler to demonstrate osteoinductivity, OsSatura is an excellent addition to our product portfolio, and we expect it to be successful commercially. We are also very pleased to work with an innovative company such as IsoTis, and to have the support of its professional marketing team in positioning OsSatura globally."

OsSatura™
OsSatura is composed of approximately 80% hydroxyapatite (HA) and 20% ß-tricalcium phosphate (ß-TCP), similar to human bone in both structure and chemical composition. It is a porous biomaterial featuring interconnected macropores and micropores with an approximate total porosity of 75%. OsSatura is not only osteoconductive, i.e., it guides bone formation through its macroporous structure, but also osteoinductive, i.e., its proprietary design actively induces bone to grow in and on the scaffold. Synthetic bone substitutes are increasingly being adopted by surgeons as a safe and efficacious alternative to allograft or autograft for orthopaedic or maxillofacial reconstruction.
IsoTis, The Leading European Biosurgery Company

IsoTis was created in Q4 2002 through the merger between Modex, a Swiss biotechnology company with a focus on skin management, and IsoTis, a Dutch biomedical company with a focus on orthopaedics. The company operates out of its official headquarters in Lausanne, Switzerland, and its facilities in Bilthoven, The Netherlands.

For detailed information on the merger, please consult [http://merger.isotis.com](http://merger.isotis.com).

BEGO- Making the future possible

BEGO is a globally-operating family-owned company with an outstanding reputation within the dental industry. Equipment and materials "Made by BEGO", the proven BEGO system and BEGO know-how are synonymous with top-quality products which combine safety and reliability. BEGO and their employees are committed to the well-being and health of the patient. The basic principles which govern the company's philosophy and culture form the foundation of BEGO: Partners in progress. Making the future possible together. For further information see [www.bego.com](http://www.bego.com).

For further information, contact:

IsoTis:
Hans Herklots
Media & investor relations
Tel: +31(0)30 229 5271
Fax: +31(0)30 228 0255 E-mail: public.relations@isotis.com

Citigate First Financial: Rochat & Partners
Barbara Jansen Christophe Lamps
Tel: +31 (0)20 575 40 80 Tel: +41 79 476 26 87
Fax: +31 (0)20 575 40 20 E-mail: clamps@rochat-pr.ch
E-mail: barbara.jansen@citigateff.nl

(Certain statements in this Press Release are “forward-looking statements”, including those that refer to management’s plans and expectations for future operations, prospects and financial condition. Such statements are based on the current expectations of the management of IsoTis S.A. only. Reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of IsoTis. Actual results could differ materially from current expectations due to a number of risk factors and uncertainties, including but not limited to the timely commencement and success of the Company’s clinical trials and research endeavors, delays in receiving U.S. FDA or other regulatory approvals (a.o. EMEA, CE), market acceptance of the Company’s products, development of competing therapies and/or technologies, the terms of any future strategic alliances, and the need for additional capital. For a more detailed description of the risk factors and uncertainties affecting the Company, refer to the Company’s reports filed from time to time with the Swiss Stock Exchange, SWX, and Euronext Amsterdam N.V. IsoTis is not obligated to update or revise any forward-looking statements, whether as a result of new information or otherwise.)